Please login to the form below

Not currently logged in
Email:
Password:

Trobalt

This page shows the latest Trobalt news and features for those working in and with pharma, biotech and healthcare.

GSK/ Valeant's Trobalt set for EU restrictions

GSK/ Valeant's Trobalt set for EU restrictions

GSK/ Valeant's Trobalt set for EU restrictions. Eye concerns prompt CHMP to recommend last-line use for the epilepsy drug. ... European regulatory advisors have recommended GlaxoSmithKline and Valeant's epilepsy drug Trobalt be restricted after safety

Latest news

  • Eisai launches epilepsy drug Fycompa in UK

    Comparing uptake, however, both Zebinix and Vimpat had slow starts before achieving fast acceleration, whereas uptake for Trobalt was “ very, very slow” according to Hendler.

  • Therapy focus: Epilepsy

    In May 2011, GlaxoSmithKline launched its new epilepsy medicine Trobalt in the UK.

  • FDA approves GSK/Valeant anti-seizure drug

    In the EU, ezogabine is known as retigabine (Trobalt). The drug received marketing authorisation in the EU in March 2011.

  • GSK launches first-in-class epilepsy drug

    GSK launches first-in-class epilepsy drug. GSK introduces Trobalt for the adjunct treatment of adults with partial-onset seizures. ... GlaxoSmithKline (GSK) has launched Trobalt (retigabine), the first in a new class of anti-epileptic drug (AED), for the

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics